TARS Quote, Financials, Valuation and Earnings

Codexis, Inc. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -228.06%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Codexis, Inc.'s return on equity of -112.54%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $84.25, signalling upside risk potential of 15.54%. On the other hand Codexis, Inc. has an analysts' consensus of $6.75 which suggests that it could grow by 310.33%. Given that Codexis, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Codexis, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.817, which suggesting that the stock is 18.347% less volatile than S&P 500. In comparison Codexis, Inc. has a beta of 2.574, suggesting its more volatile than the S&P 500 by 157.394%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Codexis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Codexis, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are larger than Codexis, Inc. quarterly revenues of $8.6M. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is higher than Codexis, Inc.'s net income of -$19.6M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Codexis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 8.11x versus 2.64x for Codexis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -82.06%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $84.25, signalling upside risk potential of 15.54%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $83.51 which suggests that it could grow by 16.72%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.817, which suggesting that the stock is 18.347% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.332, suggesting its less volatile than the S&P 500 by 66.816%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 8.11x versus 12.18x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia Corp. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -6.5%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Liquidia Corp.'s return on equity of -221.75%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $84.25, signalling upside risk potential of 15.54%. On the other hand Liquidia Corp. has an analysts' consensus of $39.00 which suggests that it could grow by 50.58%. Given that Liquidia Corp. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Liquidia Corp. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.817, which suggesting that the stock is 18.347% less volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.124, suggesting its less volatile than the S&P 500 by 87.624%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are larger than Liquidia Corp. quarterly revenues of $54.3M. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is lower than Liquidia Corp.'s net income of -$3.5M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 8.11x versus 34.61x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology, Inc. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -67975.42%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Vir Biotechnology, Inc.'s return on equity of -48.24%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $84.25, signalling upside risk potential of 15.54%. On the other hand Vir Biotechnology, Inc. has an analysts' consensus of $17.22 which suggests that it could grow by 205.9%. Given that Vir Biotechnology, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.817, which suggesting that the stock is 18.347% less volatile than S&P 500. In comparison Vir Biotechnology, Inc. has a beta of 1.266, suggesting its more volatile than the S&P 500 by 26.645%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vir Biotechnology, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are larger than Vir Biotechnology, Inc. quarterly revenues of $240K. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is higher than Vir Biotechnology, Inc.'s net income of -$163.1M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Vir Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 8.11x versus 46.05x for Vir Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.